Wells Fargo’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Wells Fargo’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-634	Closed	-$189	–	7791
2023 Q2	$189	Sell	634 -16,630	-96%	-$5.02K	﹤0.01%	6718
2023 Q1	$7.46K	Buy	+17,264	New	+$13.3K	﹤0.01%	5944
2022 Q4	–	Sell	-1,317	Closed	-$3K	–	7834
2022 Q3	$3K	Buy	1,317 +613	+87%	+$1.6K	﹤0.01%	6110
2022 Q2	$2K	Buy	704 +334	+90%	+$2.32K	﹤0.01%	6425
2022 Q1	$4K	Buy	+370	New	+$3.31K	﹤0.01%	6554

Wells Fargo's GRNA Position: Q3 2023 in Review

Wells Fargo sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 634 shares — an estimated $189 sold.

Wells Fargo first reported a position in GRNA in Q1 2022 and held it in 5 quarters. The position peaked at $7.46K in Q1 2023. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Wells Fargo reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Wells Fargo sold 634 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $189.
Wells Fargo first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2022 and held it in 5 quarters.
Wells Fargo's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $7.46K in Q1 2023.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.